Anti-CD20 monoclonal antibody that depletes B cells via complement-dependent cytotoxicity and ADCC.
Chimeric anti-CD20 monoclonal antibody that binds CD20 on B cells and depletes them primarily via complement-dependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC), and antibody-dependent cellular phagocytosis (ADCP), leading to elimination of CD20-positive B cells.
Rituximab binds CD20 on B cells and triggers complement-dependent cytotoxicity and Fc-mediated effector functions (ADCC and antibody-dependent phagocytosis), leading to lysis and clearance of CD20+ cells.
Humanized bispecific anti-CD20×CD3 monoclonal antibody that redirects T-cell cytotoxicity against CD20-positive B cells; given with step-up dosing to mitigate cytokine release syndrome.
Humanized bispecific antibody (2:1 CD20:CD3) that bridges CD20-positive B cells and CD3-positive T cells, activating T cells to form an immune synapse and kill target B cells via perforin/granzyme-mediated cytotoxicity; step-up dosing is used to mitigate cytokine release syndrome.
Glofitamab bridges CD20 on target B cells to CD3 on T cells, forming an immune synapse that activates T cells to release perforin and granzymes, killing CD20+ cells.
Type II, glycoengineered anti-CD20 monoclonal antibody that depletes B cells via enhanced ADCC, CDC, and direct cell death; used early to reduce CRS risk.
Glycoengineered humanized IgG1 type II anti-CD20 monoclonal antibody that binds CD20 on B cells; afucosylated Fc increases affinity for Fc gamma RIIIa (CD16a) to enhance antibody-dependent cellular cytotoxicity (ADCC); also triggers direct, caspase-independent cell death and can activate complement-dependent cytotoxicity (CDC), depleting CD20-positive malignant B cells.
Binds CD20 on B cells and kills via enhanced ADCC through Fc gamma RIIIa engagement, complement-dependent cytotoxicity (CDC), and direct caspase-independent cell death.
Type I chimeric anti-CD20 monoclonal antibody that depletes B cells via ADCC, CDC, and apoptosis.
Type I chimeric anti-CD20 IgG1 monoclonal antibody that binds CD20 on B cells and induces B‑cell depletion primarily via Fc‑mediated ADCC and complement‑dependent cytotoxicity, with additional direct apoptosis.
Anti‑CD20 IgG1 binds CD20 on B cells and triggers Fc‑mediated ADCC (NK cells/macrophages), complement‑dependent lysis (CDC), and some direct apoptosis via CD20 crosslinking.
Chimeric IgG1 monoclonal antibody against TNF-α; binds soluble and transmembrane TNF-α to block TNFR1/2 signaling (e.g., NF-κB/MAPK), reduce pro-inflammatory cytokines and adhesion molecules, and induce apoptosis of TNF-expressing activated T cells and macrophages; may mediate ADCC/CDC. Administered subcutaneously after switching from prior IV infliximab.
Chimeric IgG1 monoclonal antibody that binds soluble and transmembrane TNF-α, neutralizing TNF and blocking TNFR1/2 signaling (e.g., NF-κB/MAPK), thereby reducing pro‑inflammatory cytokines and adhesion molecules; can induce apoptosis of TNF-expressing activated immune cells and may mediate ADCC/CDC.
IgG1 anti–TNF-α binds transmembrane TNF on activated immune cells, triggering reverse signaling–mediated apoptosis and engaging Fc effector functions (ADCC by NK cells and CDC) to kill the target-expressing cells.